New drug could finally stop deadly fatty liver disease
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UC San Diego researchers reported that the experimental drug ION224 significantly improved liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH).
- ION224 blocks the liver enzyme DGAT2, which is responsible for fat production and storage, thereby targeting the root cause of fat accumulation and inflammation.
- Phase IIb trial enrolling 160 U.S. adults with MASH and mild‑to‑moderate fibrosis administered monthly ION224 injections for 51 weeks, with the highest dose achieving roughly 60% of participants showing meaningful liver health improvements versus placebo.
- Safety data indicated that ION224 was generally well tolerated, with no serious drug‑related adverse events reported.
Why it matters: MASH patients gain a therapy that reduces liver damage without weight loss, potentially lowering transplant demand and healthcare costs; insurers and pharma stand to profit, while standard weight‑loss drugs may see reduced market share.
